Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats

PLoS One. 2013 Oct 25;8(10):e76992. doi: 10.1371/journal.pone.0076992. eCollection 2013.

Abstract

The cardioprotective effects of estrogen are well recognized, but the mechanisms remain poorly understood. Accumulating evidence suggests that the local cardiac renin-angiotensin system (RAS) is involved in the development and progression of cardiac hypertrophy, remodeling, and heart failure. Estrogen attenuates the effects of an activated circulating RAS; however, its role in regulating the cardiac RAS is unclear. Bilateral oophorectomy (OVX; n = 17) or sham-operation (Sham; n = 13) was performed in 4-week-old, female mRen2.Lewis rats. At 11 weeks of age, the rats were randomized and received either 17 β-estradiol (E2, 36 µg/pellet, 60-day release, n = 8) or vehicle (OVX-V, n = 9) for 4 weeks. The rats were sacrificed, and blood and hearts were used to determine protein and/or gene expression of circulating and tissue RAS components. E2 treatment minimized the rise in circulating angiotensin (Ang) II and aldosterone produced by loss of ovarian estrogens. Chronic E2 also attenuated OVX-associated increases in cardiac Ang II, Ang-(1-7) content, chymase gene expression, and mast cell number. Neither OVX nor OVX+E2 altered cardiac expression or activity of renin, angiotensinogen, angiotensin-converting enzyme (ACE), and Ang II type 1 receptor (AT1R). E2 treatment in OVX rats significantly decreased gene expression of MMP-9, ACE2, and Ang-(1-7) mas receptor, in comparison to sham-operated and OVX littermates. E2 treatment appears to inhibit upsurges in cardiac Ang II expression in the OVX-mRen2 rat, possibly by reducing chymase-dependent Ang II formation. Further studies are warranted to determine whether an E2-mediated reduction in cardiac chymase directly contributes to this response in OVX rats.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Angiotensin I / metabolism
  • Angiotensinogen / genetics
  • Angiotensinogen / metabolism
  • Animals
  • Blotting, Western
  • Chymases / genetics
  • Chymases / metabolism
  • Estradiol / blood
  • Estradiol / metabolism
  • Estradiol / pharmacology
  • Estrogens / blood
  • Estrogens / metabolism
  • Estrogens / pharmacology*
  • Female
  • Gene Expression / drug effects
  • Immunohistochemistry
  • Mast Cells / metabolism
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Myocardium / metabolism*
  • Ovariectomy*
  • Peptide Fragments / metabolism
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins / metabolism
  • Random Allocation
  • Rats
  • Rats, Inbred Lew
  • Rats, Transgenic
  • Receptor, Angiotensin, Type 1 / genetics
  • Receptor, Angiotensin, Type 1 / metabolism
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, G-Protein-Coupled / metabolism
  • Renin / genetics
  • Renin / metabolism
  • Renin-Angiotensin System / drug effects
  • Renin-Angiotensin System / genetics
  • Renin-Angiotensin System / physiology*
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Estrogens
  • Peptide Fragments
  • Proto-Oncogene Proteins
  • Receptor, Angiotensin, Type 1
  • Receptors, G-Protein-Coupled
  • Ren2 protein, mouse
  • proto-oncogene proteins c-mas-1
  • Angiotensinogen
  • Estradiol
  • Angiotensin I
  • Chymases
  • Renin
  • Matrix Metalloproteinase 9
  • angiotensin I (1-7)